Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial

被引:5
|
作者
Sierra, Monica S. [1 ]
Tsang, Sabrina H. [1 ]
Hu, Shangying [1 ]
Porras, Carolina [2 ]
Herrero, Rolando [2 ,3 ]
Kreimer, Aimee R. [1 ]
Schussler, John [4 ]
Boland, Joseph [1 ,5 ]
Wagner, Sarah [1 ,5 ]
Cortes, Bernal [2 ]
Rodriguez, Ana C.
Quint, Wim [6 ]
van Doorn, Leen-Jan [6 ]
Schiffman, Mark [1 ]
Sampson, Joshua N. [1 ]
Hildesheim, Allan [1 ]
机构
[1] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20850 USA
[2] Fdn INCIENSA, Proyecto Epidemiol Guanacaste, Agencia Costarricense Invest Biomed, San Jose, Costa Rica
[3] Int Agcy Res Canc, Prevent & Implementat Grp, Lyon, France
[4] Informat Management Serv Inc, Silver Spring, MD USA
[5] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Canc Genom Res Lab, Frederick, MD USA
[6] DDL Diagnost Lab, Rijswijk, Netherlands
来源
JOURNAL OF INFECTIOUS DISEASES | 2021年 / 224卷 / 03期
基金
美国国家卫生研究院;
关键词
HPV infection; incidence; persistence; progression; CIN2+; HPV vaccine; ORAL-CONTRACEPTIVE USE; TERM-FOLLOW-UP; HORMONAL CONTRACEPTIVES; NATURAL-HISTORY; POOLED ANALYSIS; CANCER; PERSISTENCE; AGE; GUANACASTE; RATIONALE;
D O I
10.1093/infdis/jiaa768
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Factors that lead human papillomavirus (HPV) infections to persist and progress to cancer are not fully understood. We evaluated co-factors for acquisition, persistence, and progression of non-HPV-16/18 infections among HPV-vaccinated women. Methods. We analyzed 2153 women aged 18-25 years randomized to the HPV-vaccine arm of the Costa Rica HPV Vaccine Trial. Women were HPV DNA negative for all types at baseline and followed for approximately 11 years. Generalized estimating equation methods were used to account for correlated observations. Time-dependent factors evaluated were age, sexual behavior, marital status, hormonally related factors, number of full-term pregnancies (FTPs), smoking behavior, and baseline body mass index. Results. A total of 1777 incident oncogenic non-HPV-16/18 infections were detected in 12 292 visits (average, 0.14 infections/ visit). Age and sexual behavior-related variables were associated with oncogenic non-HPV-16/18 acquisition. Twenty-six percent of incident infections persisted for >= 1 year. None of the factors evaluated were statistically associated with persistence of oncogenic non-HPV-16/18 infections. Risk of progression to Cervical Intraepithelial Neoplasia grade 2 or worst (CIN2+) increased with increasing age (P for trend = .001), injectable contraceptive use (relative risk, 2.61 [95% confidence interval, 1.19-5.73] ever vs never), and increasing FTPs (P for trend = .034). Conclusions. In a cohort of HPV-16/18-vaccinated women, age and sexual behavior variables are associated with acquisition of oncogenic non-HPV-16/18 infections; no notable factors are associated with persistence of acquired infections; and age, parity, and hormonally related exposures are associated with progression to CIN2+.
引用
收藏
页码:503 / 516
页数:14
相关论文
共 50 条
  • [1] Association Between Common Vaginal Infections and Cervical Non-Human Papillomavirus (HPV) 16/18 Infection in HPV-Vaccinated Women
    Hu, Shang-Ying
    Tsang, Sabrina H.
    Chen, Feng
    Pan, Qin-Jing
    Zhang, Wen-Hua
    Hong, Ying
    Sampson, Joshua N.
    Hildesheim, Allan
    Zhao, Fang-Hui
    Kreimer, Aimee R.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (03): : 445 - 451
  • [2] Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial
    Hildesheim, Allan
    Wacholder, Sholom
    Catteau, Gregory
    Struyf, Frank
    Dubin, Gary
    Herrero, Rolando
    Grp, C. V. T.
    [J]. VACCINE, 2014, 32 (39) : 5087 - 5097
  • [3] Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial
    Kreimer, Aimee R.
    Gonzalez, Paula
    Katki, Hormuzd A.
    Porras, Carolina
    Schiffman, Mark
    Cecilia Rodriguez, Ana
    Solomon, Diane
    Jimenez, Silvia
    Schiller, John T.
    Lowy, Douglas R.
    van Doorn, Leen-Jan
    Struijk, Linda
    Quint, Wim
    Chen, Sabrina
    Wacholder, Sholom
    Hildesheim, Allan
    Herrero, Rolando
    [J]. LANCET ONCOLOGY, 2011, 12 (09): : 862 - 870
  • [4] Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda
    Kumakech, Edward
    Berggren, Vanja
    Wabinga, Henry
    Lillsunde-Larsson, Gabriella
    Helenius, Gisela
    Kaliff, Malin
    Karlsson, Mats
    Kirimunda, Samuel
    Musubika, Caroline
    Andersson, Soren
    [J]. PLOS ONE, 2016, 11 (08):
  • [5] Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women
    Ramanakumar, Agnihotram V.
    Goncalves, Otelinda
    Richardson, Harriet
    Tellier, Pierre
    Ferenczy, Alex
    Coutlee, Francois
    Franco, Eduardo L.
    [J]. BMC INFECTIOUS DISEASES, 2010, 10
  • [6] Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women
    Agnihotram V Ramanakumar
    Otelinda Goncalves
    Harriet Richardson
    Pierre Tellier
    Alex Ferenczy
    François Coutlée
    Eduardo L Franco
    [J]. BMC Infectious Diseases, 10
  • [7] Correlates of Human Papillomavirus Vaccination and Association with HPV-16 and HPV-18 DNA Detection in Young Women
    Feder, Molly A.
    Kulasingam, Shalini L.
    Kiviat, Nancy B.
    Mao, Constance
    Nelson, Erik J.
    Winer, Rachel L.
    Whitham, Hilary K.
    Lin, John
    Hawes, Stephen E.
    [J]. JOURNAL OF WOMENS HEALTH, 2019, 28 (10) : 1428 - 1435
  • [8] Correlation between levels of human papillomavirus (HPV)-16 and-18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine
    Schwarz, Tino F.
    Kocken, Marielle
    Petaja, Tiina
    Einstein, Mark H.
    Spaczynski, Marek
    Louwers, Jacqueline A.
    Pedersen, Court
    Levin, Myron
    Zahaf, Toufik
    Poncelet, Sylviane
    Hardt, Karin
    Descamps, Dominique
    Dubin, Gary
    [J]. HUMAN VACCINES, 2010, 6 (12): : 1054 - 1061
  • [9] Acquisition and Persistence of Human Papillomavirus 16 (HPV-16) and HPV-18 Among Men With High-HPV Viral Load Infections in a Circumcision Trial in Kisumu, Kenya
    Senkomago, Virginia
    Backes, Danielle M.
    Hudgens, Michael G.
    Poole, Charles
    Agot, Kawango
    Moses, Stephen
    Snijders, Peter J. F.
    Meijer, Chris J. L. M.
    Hesselink, Albertus T.
    Schlecht, Nicolas F.
    Bailey, Robert C.
    Smith, Jennifer S.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (05): : 811 - 820
  • [10] OCCURRENCE OF HUMAN PAPILLOMAVIRUS DNA TYPE-16 AND TYPE-18 (HPV-16/18) IN CERVICAL SMEARS AS COMPARED TO CYTOLOGICAL FINDINGS
    KOCHEL, HG
    TEICHMANN, A
    ECKARDT, N
    ARENDT, P
    KUHN, W
    THOMSSEN, R
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1990, 31 (02) : 145 - 152